Ferroptosis: Pathway, Mechanisms, and Therapeutic Implications

Cell death is a fundamental biological process essential for development, tissue homeostasis, and defense against disease. Traditionally, research on programmed cell death has focused on apoptosis, necroptosis, and autophagy. However, in 2012, a new form of regulated cell death was described: ferroptosis. Unlike apoptosis or necroptosis, ferroptosis is iron-dependent and driven by the accumulation of toxic lipid peroxides in cellular membranes.

Ferroptosis is characterized by distinct morphological, biochemical, and genetic features. Cells undergoing ferroptosis typically show condensed mitochondria with reduced cristae, but without the nuclear fragmentation seen in apoptosis. Biochemically, ferroptosis arises from the disruption of redox homeostasis, mainly through the depletion of glutathione and inactivation of the antioxidant enzyme glutathione peroxidase 4 (GPX4).

Its discovery has opened new perspectives in cancer biology, neurodegenerative diseases, and therapeutic development. Understanding its molecular basis provides a promising path toward targeted therapies that can selectively eliminate diseased cells resistant to conventional treatments.

In this article, we will explore:

• The molecular mechanisms regulating ferroptosis,
• Key inducers and inhibitors,
• Its role in cancer and other diseases, and
• Experimental approaches to study ferroptosis

Molecular Mechanism of Ferroptosis

Ferroptosis is a regulated cell death pathway that fundamentally depends on iron metabolism and lipid peroxidation. Unlike apoptosis or necroptosis, it is not mediated by caspases but by the uncontrolled accumulation of reactive oxygen species (ROS) within lipid membranes. The process can be understood through three central mechanisms: iron homeostasis, lipid metabolism, and antioxidant defense systems.

1. Iron Metabolism and ROS Generation

Iron plays a pivotal role in ferroptosis through its ability to catalyze the Fenton reaction, which generates highly reactive hydroxyl radicals from hydrogen peroxide. These radicals initiate lipid peroxidation, damaging polyunsaturated fatty acids (PUFAs) within membranes.

• Iron overload or disrupted iron storage increases susceptibility to ferroptosis.
• Proteins such as transferrin receptor (TFRC) and ferritin are central regulators of cellular iron balance.

2. Lipid Peroxidation

The hallmark of ferroptosis is peroxidation of membrane phospholipids rich in PUFAs.

• Enzymes such as ACSL4 (acyl-CoA synthetase long-chain family member 4) and LPCAT3 (lysophosphatidylcholine acyltransferase 3) incorporate PUFAs into phospholipids, making them substrates for peroxidation.
• Oxidation of these phospholipids leads to the generation of toxic lipid peroxides that compromise membrane integrity.

3. Antioxidant Defense Systems

Cells possess protective mechanisms to suppress ferroptosis. The most critical is the glutathione (GSH)–glutathione peroxidase 4 (GPX4) axis.

• System Xc– (SLC7A11/SLC3A2) imports cystine in exchange for glutamate, enabling the synthesis of GSH.
• GPX4 uses GSH to reduce lipid hydroperoxides into non-toxic lipid alcohols.
• Inhibition of System Xc– or GPX4 (e.g., by erastin or RSL3) drives ferroptosis by preventing detoxification of lipid ROS.

4. Additional Regulators

• NRF2: Master regulator of antioxidant responses; its activation suppresses ferroptosis.
• P53: A tumor suppressor that can either promote or inhibit ferroptosis depending on context.
• FSP1 (Ferroptosis suppressor protein 1): Provides a GPX4-independent defense mechanism by reducing coenzyme Q10, preventing lipid peroxidation.

Ferroptosis Inducers and Inhibitors

Ferroptosis can be pharmacologically modulated by small molecules that either promote or prevent its occurrence.

Ferroptosis Inducers

Inducers of ferroptosis function by disrupting antioxidant defenses or enhancing lipid peroxidation.

1. Erastin
   • One of the first identified ferroptosis inducers.
   • Inhibits System Xc–, blocking cystine import and depleting glutathione, leading to GPX4 inactivation.
2. RSL3 (RAS-selective lethal 3)
   • Directly binds and inhibits GPX4, preventing the detoxification of lipid hydroperoxides.
3. Sorafenib
   • A multi-kinase inhibitor used in hepatocellular carcinoma therapy.
   • Also acts as a ferroptosis inducer by inhibiting System Xc–.
4. Other small molecules
   • Compounds such as FIN56 and FINO2 enhance lipid peroxidation through distinct mechanisms, further demonstrating the diversity of ferroptosis induction strategies.

Ferroptosis Inhibitors

Inhibitors of ferroptosis are equally important, as they provide insights into regulatory pathways and potential protective strategies in diseases such as neurodegeneration.

1. Ferrostatin-1 (Fer-1)
   • A lipophilic radical-trapping antioxidant.
   • Prevents lipid ROS accumulation and protects against ferroptotic cell death.
2. Liproxstatin-1
   • A potent ferroptosis inhibitor with similar radical-scavenging properties.
   • Effective in both in vitro and in vivo models of ferroptosis.
3. Iron chelators (e.g., Deferoxamine)
   • Reduce intracellular iron availability, limiting ROS production via the Fenton reaction.
4. Genetic regulators
   • Overexpression of FSP1 or activation of the NRF2 antioxidant pathway provides endogenous resistance to ferroptosis.

Ferroptosis inducers and inhibitors have become indispensable tools in research, enabling the dissection of ferroptotic signaling and offering potential translational applications. Inducers hold promise in cancer therapy, where triggering ferroptosis may overcome resistance to apoptosis, while inhibitors are under investigation for neuroprotection in degenerative disorders.

Ferroptosis in Cancer Biology

The link between ferroptosis and cancer biology has attracted considerable attention over the past decade. Ferroptosis is emerging as a double-edged sword in oncology: while it can act as a tumor-suppressive mechanism by eliminating malignant cells, certain cancers exploit ferroptosis resistance to sustain survival.

Tumor Suppression through Ferroptosis

Many tumor cells are inherently sensitive to ferroptosis due to their altered metabolism.

• Iron metabolism dysregulation in cancer cells creates a favorable environment for ferroptotic death, as excess intracellular iron accelerates lipid peroxidation.
• Oncogenic signaling pathways often shift redox balance toward oxidative stress, making cancer cells more vulnerable to ferroptosis when antioxidant defenses are impaired.
• Experimental evidence shows that activating ferroptosis can suppress tumor growth in multiple models, including hepatocellular carcinoma, breast cancer, glioblastoma, and bladder cancer.

Mechanisms of Ferroptosis Resistance in Cancer

Despite this vulnerability, many tumors develop resistance mechanisms:

• Upregulation of System Xc– (SLC7A11) enhances cystine import and glutathione synthesis.
• GPX4 overexpression provides strong protection against lipid peroxidation.
• NRF2 activation promotes a broad antioxidant response, limiting ferroptotic sensitivity.
• P53, depending on cellular context, can either promote ferroptosis (by repressing SLC7A11) or suppress it (through induction of p21 and cell cycle arrest).

Ferroptosis and the Tumor Microenvironment

The tumor microenvironment (TME) significantly influences ferroptosis.

• Immune cells, such as CD8+ T lymphocytes, can promote ferroptosis in cancer cells through interferon-γ–mediated suppression of System Xc–.
• Conversely, stromal cells and cancer-associated fibroblasts may contribute to ferroptosis resistance by providing metabolic support.

Therapeutic Implications

Exploiting ferroptosis in cancer treatment is a promising strategy:

• Combination therapies: Ferroptosis inducers combined with chemotherapy, radiotherapy, or immunotherapy enhance tumor cell killing.
• Overcoming resistance: Ferroptosis can eliminate apoptosis-resistant tumor cells, offering a way to bypass classical resistance mechanisms.
• Precision medicine: Identifying ferroptosis biomarkers (e.g., ACSL4, GPX4, SLC7A11 expression) may help stratify patients likely to benefit from ferroptosis-targeted treatments.

Ferroptosis thus represents both a vulnerability and a survival challenge for tumors. The balance between induction and resistance determines its role in cancer progression and therapy.

Beyond Cancer

Although initially studied in the context of oncology, ferroptosis has been implicated in a wide range of diseases beyond cancer. Its involvement in conditions characterized by oxidative stress and iron imbalance highlights its broader biological significance.

Neurodegenerative Diseases

Neurodegeneration is closely linked to lipid peroxidation and dysregulated iron metabolism, both central to ferroptosis.

• Parkinson’s disease: Elevated iron levels in the substantia nigra and increased lipid ROS contribute to dopaminergic neuron death. Ferroptosis inhibitors such as ferrostatin-1 have shown protective effects in experimental models.
• Alzheimer’s disease: Abnormal iron deposition and oxidative damage to neuronal membranes suggest a role for ferroptosis in disease progression.
• Huntington’s disease and amyotrophic lateral sclerosis (ALS): Evidence indicates that ferroptosis contributes to neuronal loss through glutathione depletion and GPX4 inactivation.

Ischemia-Reperfusion Injury

Ferroptosis also plays a major role in ischemia-reperfusion injury, which occurs in conditions such as stroke, myocardial infarction, and organ transplantation.

• During reperfusion, the sudden reintroduction of oxygen triggers oxidative stress and lipid peroxidation.
• Iron accumulation exacerbates this process, making ferroptosis a key contributor to tissue damage.
• Ferroptosis inhibitors have demonstrated protective effects in experimental models of stroke and heart attack.

Infectious and Inflammatory Diseases

• In bacterial infections, ferroptosis may serve as a host defense mechanism by limiting pathogen survival. However, excessive ferroptosis can also aggravate tissue damage.
• In inflammatory disorders, such as acute pancreatitis or inflammatory bowel disease, deregulated ferroptotic death of epithelial and immune cells contributes to disease severity.

Metabolic and Other Disorders

• Liver diseases: Non-alcoholic steatohepatitis (NASH) and alcoholic liver disease involve oxidative stress and iron dysregulation, conditions that sensitize hepatocytes to ferroptosis.
• Kidney injury: Ferroptosis has been linked to acute kidney injury through mechanisms involving glutathione depletion and lipid ROS accumulation.

Experimental Models and Detection

The study of ferroptosis requires well-defined experimental models and reliable detection methods. Because ferroptosis is mechanistically distinct from apoptosis, necroptosis, and other forms of cell death, its identification relies on a combination of morphological, biochemical, and genetic approaches.

In Vitro Models

Cell culture systems have been central to elucidating ferroptotic pathways.

• Cancer cell lines such as HT-1080 (fibrosarcoma) and HepG2 (hepatocellular carcinoma) are commonly used due to their sensitivity to ferroptosis inducers.
• Primary neurons and induced pluripotent stem cell (iPSC)-derived neurons provide models for studying ferroptosis in neurodegenerative contexts.
• Pharmacological inducers such as erastin and RSL3 are used to trigger ferroptosis, while inhibitors like ferrostatin-1 confirm ferroptosis-specific cell death.

In Vivo Models

Animal studies are essential for understanding ferroptosis in physiology and disease.

• Transgenic mice with altered expression of GPX4, ACSL4, or SLC7A11 have been used to demonstrate ferroptosis in development and pathology.
• Ischemia-reperfusion models in the brain, heart, and kidneys highlight the role of ferroptosis in organ damage.
• Tumor xenografts in mice allow investigation of ferroptosis-inducing therapies in cancer biology.

Morphological Features

Electron microscopy has revealed distinct ultrastructural changes in ferroptotic cells:

• Shrunken mitochondria with condensed membrane densities.
• Reduced or absent mitochondrial cristae.
• Intact nuclei without chromatin condensation (in contrast to apoptosis).

Biochemical and Molecular Markers

Several molecular indicators are used to detect ferroptosis:

• Lipid ROS accumulation measured using probes such as C11-BODIPY.
• Malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE) as byproducts of lipid peroxidation.
• Glutathione depletion and inactivation of GPX4.
• Altered expression of SLC7A11, ACSL4, and FSP1, which modulate ferroptotic sensitivity.

Genetic Approaches

• Knockout or knockdown studies targeting GPX4 or SLC7A11 confirm their central roles in ferroptosis.
• CRISPR-Cas9 screening has identified novel regulators and resistance mechanisms, expanding the landscape of ferroptosis research.

References

1. Li J, Cao F, Yin HL, Huang ZJ, Lin ZT, Mao N, Sun B, Wang G. Ferroptosis: past, present and future. Cell Death Dis. 2020 Feb 3;11(2):88. doi: 10.1038/s41419-020-2298-2.
2. Liang D, Minikes AM, Jiang X. Ferroptosis at the intersection of lipid metabolism and cellular signaling. Mol Cell. 2022 Jun 16;82(12):2215-2227. doi: 10.1016/j.molcel.2022.03.022.
3. Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 2021 Feb;31(2):107-125. doi: 10.1038/s41422-020-00441-1.
4. Zhou, M.; Xu, K.; Ge, J.; Luo, X.; Wu, M.; Wang, N.; Zeng, J. Targeting Ferroptosis in Parkinson’s Disease: Mechanisms and Emerging Therapeutic Strategies. Int. J. Mol. Sci. 2024, 25, 13042. https://doi.org/10.3390/ijms252313042
5. Majerníková, N., Marmolejo-Garza, A., Salinas, C.S. et al. The link between amyloid β and ferroptosis pathway in Alzheimer’s disease progression. Cell Death Dis 15, 782 (2024). https://doi.org/10.1038/s41419-024-07152-0

FAQ